Efficacy and Safety of Gliclazide versus Glimepiride in T2DM Patients: A Systematic Review
Abstract
This systematic review compares the efficacy and safety of gliclazide and glimepiride in managing type 2 diabetes mellitus (T2DM). A comprehensive search was conducted in multiple databases, including PubMed and Cochrane Library, to identify relevant randomised controlled trials and observational studies. Five studies were included based on pre-defined eligibility criteria, focussing on glycaemic control (HbA1c, fasting blood glucose, and post-prandial blood glucose) and safety outcomes like hypoglycaemia and cardiovascular events. Data were extracted and synthesised using established systematic review methodologies, and risk of bias was assessed with Cochrane tools. Both gliclazide and glimepiride effectively reduced HbA1c, but gliclazide showed a lower risk of hypoglycaemia. However, elderly patients using gliclazide had an increased risk of severe hypoglycaemia and fractures. This review indicates that while both drugs are effective, gliclazide may have a safer profile in middle-aged adults, with glimepiride potentially being a better option for older adults.
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.